Stack Financial Management Inc raised its stake in the shares of Johnson & Johnson (NYSE:JNJ – Get a rating) by 0.4% during the 1st quarter, according to the company in its latest filing with the Securities and Exchange Commission (SEC). The fund held 99,577 shares of the company after buying an additional 429 shares during the period. Stack Financial Management Inc’s holdings in Johnson & Johnson were worth $17,648,000 when it last filed with the SEC.
Several other institutional investors and hedge funds also changed their positions in the stock. Magnolia Capital Management Ltd. increased its holding in Johnson & Johnson shares by 0.5% in the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company worth $1,978,000 after buying 55 more shares in the last quarter. Howard Financial Services LTD. increased its holding of Johnson & Johnson shares by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company worth $489,000 after buying 57 more shares in the last quarter. American Financial Advisors LLC increased its holding in Johnson & Johnson shares by 2.1% in the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company worth $481,000 after buying 57 more shares in the last quarter. Capital Investment Counsel Inc increased its holdings of Johnson & Johnson shares by 0.8% during the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company worth $1,334,000 after buying 59 additional shares in the last quarter. Finally, Kwmg LLC increased its stake in Johnson & Johnson by 2.6% in the first quarter. Kwmg LLC now owns 2,354 shares of the company valued at $417,000 after acquiring 59 additional shares in the last quarter. 68.78% of the shares are currently held by institutional investors and hedge funds.
Changes to analyst ratings
JNJ has been the subject of a number of recent analyst reports. Daiwa Capital Markets launched coverage on Johnson & Johnson in a Wednesday, June 22 report. They issued an “outperformance” rating on the stock. UBS Group reduced its price target on Johnson & Johnson from $185.00 to $180.00 in a Thursday, July 21 report. Raymond James raised its price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a Wednesday, April 20 report. Credit Suisse Group raised its price target on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a Wednesday, April 20 report. Finally, Citigroup reduced its price target on Johnson & Johnson from $205.00 to $201.00 in a Wednesday, July 20 research report. Four investment analysts gave the stock a hold rating, five gave the stock a buy rating and one gave the stock a high buy rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “moderate buy” and an average target price of $189.89.
Insider buying and selling
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares in a trade dated Friday, June 10. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company, valued at $12,336,803. The sale was disclosed in an SEC filing, available at this link. In related news, CAO Robert J. Decker sold 8,462 shares of the company in a trade that took place on Thursday, May 26. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accountant now owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a document filed with the SEC, accessible via this hyperlink. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a transaction that took place on Friday, June 10. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. Disclosure of this sale can be found here. 0.35% of the shares are currently held by company insiders.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $173.91 on Tuesday. The company has a market capitalization of $457.63 billion, a PE ratio of 25.31, a growth price-earnings ratio of 3.32 and a beta of 0.59. The company’s fifty-day moving average price is $175.84 and its 200-day moving average price is $174.50. The company has a debt ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get a rating) last released its quarterly earnings data on Tuesday, July 19. The company reported earnings per share (EPS) of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company posted revenue of $24.02 billion in the quarter, versus a consensus estimate of $23.85 billion. In the same quarter a year earlier, the company posted earnings per share of $2.48. Johnson & Johnson revenue for the quarter increased 3.0% year over year. On average, sell-side analysts expect Johnson & Johnson to post earnings per share of 10.05 for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Investors of record on Tuesday, August 23 will receive a dividend of $1.13 per share. The ex-dividend date is Monday, August 22. This represents an annualized dividend of $4.52 and a yield of 2.60%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.